The New England journal of medicine, 2020-03, Vol.382 (13), p.1208-1218
- Windecker, Stephan
- Latib, Azeem
- Kedhi, Elvin
- Kirtane, Ajay J
- Kandzari, David E
- Mehran, Roxana
- Price, Matthew J
- Abizaid, Alexandre
- Simon, Daniel I
- Worthley, Stephen G
- Zaman, Azfar
- Hudec, Martin
- Poliacikova, Petra
- Abdul Ghapar, A. Kahar bin
- Selvaraj, Kamaraj
- Petrov, Ivo
- Mylotte, Darren
- Pinar, Eduardo
- Moreno, Raul
- Fabbiocchi, Franco
- Pasupati, Sanjeevan
- Kim, Hyo-Soo
- Aminian, Adel
- Tie, Charles
- Wlodarczak, Adrian
- Hur, Seung-Ho
- Marx, Steven O
- Jankovic, Ivana
- Brar, Sandeep
- Bousquette, Lisa
- Liu, Minglei
- Stone, Gregg W
2020
Details
- Autor(en) / Beteiligte
- Windecker, Stephan
- Latib, Azeem
- Kedhi, Elvin
- Kirtane, Ajay J
- Kandzari, David E
- Mehran, Roxana
- Price, Matthew J
- Abizaid, Alexandre
- Simon, Daniel I
- Worthley, Stephen G
- Zaman, Azfar
- Hudec, Martin
- Poliacikova, Petra
- Abdul Ghapar, A. Kahar bin
- Selvaraj, Kamaraj
- Petrov, Ivo
- Mylotte, Darren
- Pinar, Eduardo
- Moreno, Raul
- Fabbiocchi, Franco
- Pasupati, Sanjeevan
- Kim, Hyo-Soo
- Aminian, Adel
- Tie, Charles
- Wlodarczak, Adrian
- Hur, Seung-Ho
- Marx, Steven O
- Jankovic, Ivana
- Brar, Sandeep
- Bousquette, Lisa
- Liu, Minglei
- Stone, Gregg W
- Titel
- Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
- Ist Teil von
- The New England journal of medicine, 2020-03, Vol.382 (13), p.1208-1218
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial involving patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1910021Titel-ID: cdi_swepub_primary_oai_prod_swepub_kib_ki_se_143404752
- Format
- –
- Schlagworte
- Anticoagulants, Aspirin, Bleeding, Cardiovascular & respiratory systems, Cardiovascular disease, Coatings, Coronary Artery Disease - therapy, Coronary Thrombosis - etiology, Coronary Thrombosis - mortality, Coronary Thrombosis/etiology/mortality, Drug delivery, Drug dosages, Drug Therapy, Combination, Drug-eluting stents, Drug-Eluting Stents - adverse effects, Equipment and supplies, H4GXR80IZE (zotarolimus), Heart, Heart attacks, Heart Diseases - mortality, Hemorrhage - chemically induced, Human health sciences, Humans, Immunosuppressive Agents, Immunosuppressive Agents - administration & dosage, Implants, Kaplan-Meier Estimate, Laboratories, Medicin och hälsovetenskap, Myocardial infarction, Patient outcomes, Patients, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Platelet Aggregation Inhibitors - adverse effects, Platelet Aggregation Inhibitors - therapeutic use, Platelet Aggregation Inhibitors/adverse effects/therapeutic use, Polymers, Polymers in medicine, Prosthesis Design, Safety and security measures, Sciences de la santé humaine, Single-Blind Method, Sirolimus - administration & dosage, Sirolimus - analogs & derivatives, Sirolimus/administration & dosage/analogs & derivatives, Stents, Systèmes cardiovasculaire & respiratoire, Thrombosis, Transluminal angioplasty, U36PGF65JH (umirolimus), W36ZG6FT64 (Sirolimus)